57.100
|
NHSN Registration Form
|
No change
|
No change
|
N/A
|
57.101
|
Facility Contact
Information
|
No change
|
No change
|
N/A
|
57.103
|
Patient Safety
Component-Annual Hospital Survey
|
No change
|
Increase
the number of reporting facilities from 5,000 to 6,000. Increase
in time burden of 15 minutes.
Question
revised for #1, #6,#7, #9, #21#11,#24, #25-#35
Response
options modified for questions #2, #5, #6, #9, #16-#19,
New
required question added #5, #8, #10,#22, #25-#30, #31-40
New
optional questions added for #41-50
|
Additional
health systems and hospitals continue to onboard into the
Patient Safety Component of NHSN, therefore, we’ve
increased the estimated number of facilities that will report
these data in the calendar year 2019. Time burden will increase
form 60 minutes to 75 minutes.
Modified
question language for question #1 to include “bacterial”
for the type of antimicrobial susceptibility testing. Adding the
word was done to clarify the existing question and differentiate
it from the same question about fungal testing later (#7).
Wording clarification for question #6 added. For #9 the question
was enhanced to include testing that occurs at both facilities
and outside laboratory testing. The emergence of Candida auris
in the U.S it is more important to get a sense of how many
facilities have access to labs (whether it is their own or
outside lab) that use methods that can accurately identify C.
auris. Question #21 contains clarification to include patients
admitted to non-NICU settings in order to differentiate from a
new question (#22) added. Question
#11 was removed because CDC no longer recommends production of
antibiograms, which removes the utility of the responses.
Question #24 was removed because it did not produce useful
information to our prevention and response branch upon analysis.
Question #25-35 were replaced by questions #31-40 on the new
form to align better with the Core Elements of Hospital
Antibiotic Stewardship guidelines from CDC to better describe
current stewardship programs.
New
response options included on #2 to reflect current advanced
testing instruments (ATI) being used bacterial antimicrobial
susceptibility testing .Also a wording correction for one of the
test method names that was previously “Other micro broth
dilution method”; it’s been corrected to “Other
broth microdilution method”. New response options added to
#5 to include updated ATI for carbapenemase testing. Answer
options for antimicrobial susceptibility testing (AST) methods
on question #6, “Vitek (legacy)”Microscan Walkaway
rapid” have become obsolete and have been removed. Methods
“MicroScan WalkAway”, “MicroScan autoSCAN”,
“Birby-Bauer disk diffusion”, and Accelerate Pheno”
were all added as options to address an update in new AST
methods technology. Response option for #9 “Broth
macrodilution” was removed due to it becoming obsolete.
Response options for questions #16-19 have been changed in order
to remove the mutually exclusive categorization. Respondents
will now select “Yes” “No” or “Not
applicable” to the question. If “Yes” is
selected.
Secondary
question added to #5 to gather information about a policy in
place to notify hospital personnel when carbapenemase is
detected to inform prevention and protocol practices implemented
by DHQP. Question #8 added because 50% of C. auris isolates in
the U.S. are from non-blood sites and there is currently no
question on the survey to enumerate this appropriately. Question
#10 added to capture further details about the scenario’s
that exist for antifungal susceptibility testing (AFST) to be
conducted. AFST is typically not included in routine Candida
testing that other survey questions inquire about. Question #22
added to specifically identify routine screening for MRSA of
neonatal units. Neonatal indication screening of MRSA differs
greatly from adults and pediatrics, and in turn, predictors of
antimicrobial use would be different. Question #25-30 added to
assist in with the creation neonatal-specific Standardized
Antimicrobial Administration Ratio (SAAR), a benchmark metric
that we hope will assist hospitals with antibiotic stewardship
efforts in neonatal intensive care units, special care
nurseries, and well newborn nurseries. Current adult and
pediatric SAARs adjust only for unit/location- and
hospital-level characteristics, such as bed size, teaching
status, or location type. Neonatal antimicrobial use differs
greatly from adult and pediatric use, both in indication for use
and agents selected for therapy, and therefore predictors of
antimicrobial use differ. Patient level data is not currently
reported to the AU Option, but certain patient-level
characteristics in neonates are known to be associated with
antimicrobial use. In order to capture these important
predictors of antimicrobial use in the absence of patient-level
data, survey questions are needed that capture this data in
aggregate. We ultimately plan to incorporate information
collected through these survey questions as hospital-level
factors in our predictive models to assess their association
with neonatal AU. Questions #31-40 are replacing previous
questions related to Antibiotic Stewardship Practices (ASP) on
the previous survey. Analysis conducted found that the previous
ASP survey questions did not provide enough description of
facilities current Antibiotic Stewardship Programs based on the
CDC developed Core Elements of Hospital Antibiotic Stewardship
guidelines. These guidelines are part of the larger CDC action
plan of Combating Antibiotic-resistant Bacteria. The new
questions will add granularity to provide a better depiction of
hospitals current stewardship programs.
New
optional questions about hospitals antibiotic stewardship
practices were added to add supplemental detail from required
questions #31-40 of the same topic.
These
changes will increase the overall estimated burden of this form
by 2,500 hours.
|
57.105
|
Group Contact Information
|
No change
|
No change
|
N/A
|
57.106
|
Patient Safety Monthly
Reporting Plan
|
No change
|
Added PedVAE
responses under the Device Associated Module
|
An
addition was made to the response options under the Device
Associated Module of the form to accommodate the new NHSN
Pediatric Ventilator Associated Event (PedVAE) surveillance
module scheduled to be released in 2019.
These changes will not
affect the overall estimated burden of this form.
|
57.108
|
Primary Bloodstream
Infection (BSI)
|
No change
|
New
response options are added under Risk Factor section.
Response
options were changed from optional to required for Hemodialysis,
ECMO and VAD devices present.
|
Added
optional fields “known or suspected Munchausen’s
Syndrome by Proxy (MSBP); Diagnosis of Epidermolysis Bullosa
(EB;, Group B Streptococcus in the first 6 days of life’
Pus at vascular access site with matching organism in the blood
collected in the IWP; and patient injection into vascular access
line to further identify risk factors that can be associated
with a BSI but can potentially be excluded from CLABSI
surveillance. Collection of this data will aide in the analysis
of BSIs not associated with central line use.
Changed
response for Hemodialysis catheter present, ECMO present or VAD
device present from optional (2018) to required (2019).Have been
unable to capture data to date due to CDA import requirements
for “in-plan” data. Once required these options will
aide in analysis of BSIs not associated with central line use.
This
change does not affect the estimated burden of this form because
users had to make these determinations in previous years to
determine if CLABSI criteria were met. This year they are merely
required to record the information.
|
57.111
|
Pneumonia (PNEU)
|
No change
|
No change
|
N/A
|
57.112
|
Ventilator-Associated
Event
|
No change
|
No change
|
N/A
|
57.113
|
Pediatric
Ventilator-Associated Event (PedVAE)
|
No change
|
Removed
“specific event” response option.
|
Under
the event details section of the form, the PedVAC was removed
due to the algorithm being single tiered and there only being
one specific event for PedVAE.
This
change does not affect the estimated burden of this form.
|
57.114
|
Urinary Tract Infection
(UTI)
|
No change
|
Response
options were updated to include additional symptom under the
Event Details Section.
|
This
change will add the symptom, “Suprapubic tenderness”
to better align the response options with NHSN protocols, which
were updated in 2017.
This change does not
affect the estimated burden of this form.
|
57.115
|
Custom Event
|
No change
|
No change
|
N/A
|
57.116
|
Denominators for Neonatal
Intensive Care Unit (NICU)
|
No change
|
Response
options were changed from optional to required for Hemodialysis,
ECMO and Ventricular Assist Devices present.
Reporting
of ventilator days for birth weight is conditionally required.
Added
PedVAE Optional Denominators for gestational age requesting
optional PT, VNT, and EMV.
|
Changed
response to Hemodialysis catheter present, ECMO present or VAD
device present from optional (2018) to required (2019).Have been
unable to capture data to date due to CDA import requirements
for “in-plan” data. Once required these options will
aid in the analysis of BSIs not associated with central line
use.
There
is now a ventilator associated event available for NICU
locations requiring related denominator reporting.
There
is now a ventilator associated event available for NICU
locations requiring related denominator reporting, in which CDC
has provided an option to accommodate facilities that are
reporting requested data.
This change does not
affect the estimated burden of this form.
|
57.117
|
Denominators for Specialty
Care Area (SCA)/Oncology (ONC)
|
No change
|
Response
options were changed from optional to required for Hemodialysis,
Extracorporeal Membrane Oxygenation (ECMO).
Decrease the
number of reporting facilities from 6,000 to 2,000.
|
Changed
response to Hemodialysis catheter present, ECMO present or
Ventricular Assist Device (VAD) present from optional (2018) to
required (2019). NHNS has been unable to capture data to date
due to the CDA import.
The
number of reporting facilities were re-evaluated by NHSN and it
has been determined after conducting some additional analysis
that this form is only being used by approximately 2,000
facilities compared to what was estimated last year.
This change will
decrease the overall estimated burden for this form by 180,480
hours.
|
57.118
|
Denominators for Intensive
Care Unit (ICU)/Other Locations (Not NICU or SCA)
|
No change
|
No change
|
N/A
|
57.120
|
Surgical Site Infection
(SSI)
|
No change
|
No change
|
N/A
|
57.122
|
HAI Progress Report State
Health Department Survey
|
N/A
|
New
Form added to the Patient Safety Component of NHSN.
Time burden will
increase by 45 minutes annually with the addition of this form.
|
The
new patient safety component form will be an optional form that
is completed by a randomly selected group of Health Departments
that participate in HAI surveillance in their respective
jurisdictions and also participate in reporting data and
conducting surveillance activities and oversee programs. This
form will provide NHSN with data on regulatory and legislative
influences on HAI reporting within the states. To collect
information from all states and territory health departments on
healthcare associated infection (HAI) reporting requirements and
data validation activities that were in place during the 2017
calendar year Information collected from this survey is used to
populate technical tables in the annual release of the National
and State Healthcare Associated Infection Progress Report. The
report helps identify the progress that is being made in the
prevention of HAI's at the state and national level. Information
from the survey is justified with state-level data that monitors
the number of facilities reporting and total HAI events. Having
an understanding of whether the state has validated their HAI
data, or has a state mandate to report such HAI data, is very
helpful when interpreting the state-level HAI incidence data
presented in CDC’s report.
This form will increase
the overall reporting burden of this form by 41 hours.
|
57.121
|
Denominator for Procedure
|
No change
|
Removed the
“transoral” Response options under the Procedure
Details Section.
|
The
“transoral” approach/technique has been removed to
accommodate consistency with supporting documents and the NHSN
application.
This change does not
affect the estimated burden of this form.
|
57.123
|
Antimicrobial Use and
Resistance (AUR)-Microbiology Data Electronic Upload
Specification Tables
|
No change
|
Added
seven new organisms for surveillance
Added
11 antimicrobials and removed eight antimicrobials for a net
gain of 3 additional drugs to report for antimicrobial
susceptibility testing
Increased
the number of facilities reporting data from 350 to 1,000.
|
The
seven new organisms were added as each is currently found in
hospital settings. Monitoring these additional organisms and
their antimicrobial susceptibility profiles will aid hospitals
in clinical decision making and assist with prioritizing
transmission prevention efforts.
The
antimicrobials that are required to be reported for
susceptibility testing were reviewed and updated per the most
recent Clinical and Laboratory Standards Institute (CLSI)
standards.
Additional
health systems and hospitals continue to onboard into the
Antimicrobial Resistance Option for reporting within NHSN.
Therefore, we have increased the estimated number of facilities
that will report these data in the calendar year 2019.
This change will
increase the overall estimated burden for this form for 650
hours.
|
57.124
|
Antimicrobial Use and
Resistance (AUR)-Pharmacy Data Electronic Upload Specification
Tables
|
No change
|
Added
two new antimicrobials for surveillance
Increased
the number of facilities reporting data from 800 to 2,000
|
Two
new antimicrobials were recently approved by FDA and will be
used by hospitals for treating infections. By capturing the use
of these two new drugs, hospitals will be able to better track
use and implement stewardship interventions if needed.
Additional
health systems and hospitals continue to onboard into the
Antimicrobial Use Option reporting within NHSN. Therefore, we’ve
increased the estimated number of facilities that will report
these data in the calendar year 2019.
These changes will
decrease the overall estimated burden for this form by 1,200
hours.
|
57.125
|
Central Line Insertion
Practices Adherence Monitoring
|
No change
|
No change
|
N/A
|
57.126
|
MDRO or CDI Infection Form
|
No change
|
No change
|
N/A
|
57.127
|
MDRO and CDI Monthly
Denominator Form
|
MDRO and CDI Prevention
Process and Outcome Measures Monthly Monitoring
|
Title
updated from: “MDRO and CDI Prevention Process and Outcome
Measures Monthly Reporting” changed to “MDRO and CDI
Monthly. Denominator Form”
Revised
form instructions on line #2 and #3 to clarify how users can
calculate their counts.
Removed
“MDRO Encounters” as a data entry field on the form.
Removed
“CDI Encounters” as a data entry field on the form.
Section
2: “MDRO & CDI Infection Surveillance or LabID Event
Reporting” changed to “Organism
Selection/Confirmation of No Events.”
No. of reporting
facilities decreased from 6000 to 4930
|
The
title was revised to make the form title more concise and easier
for users identify.
Form
instructions on line #2 and #3 were updated to provide more
descriptive instructions and guidance to ensure that users are
correctly calculating patient days and admissions.
This
data entry field is ambiguous and no longer needed.
This
data entry field is ambiguous and no longer needed.
The
revision will make
section title more concise and easier to identify by reporting
facilities and NHSN users.
Reporting
facilities decreased to account for CMS regulatory changes.
The changes decrease
the overall burden of this form by 6,420 hours.
|
57.128
|
Laboratory-identified MDRO
or CDI Event
|
No change
|
No. of
reporting facilities decreased from 6000 to 4930
|
Reporting
facilities decreased to account for CMS regulatory changes.
The changes decrease
the overall burden of this form by 85,600 hours.
|
57.129
|
Adult Sepsis
|
No change
|
No change
|
N/A
|
57.137
|
Long-Term Care Facility
Component – Annual Facility Survey
|
No change
|
No change
|
N/A
|
57.138
|
Laboratory-identified MDRO
or CDI Event for LTCF
|
No change
|
No change
|
N/A
|
57.139
|
MDRO and CDI LabID Event
Reporting
Monthly Summary Data
for LTCF
|
No change
|
Add
“CDI Treatment Starts” variable.
Increase
time burden for data collection by 10 minutes
|
Adding
the “CDI Treatment Starts” variable will help
facilities determine whether low CDI event rates might be due to
empiric CDI treatment practices. A new process measure will be
incorporated into the monthly summary data on CDI for LTCFs in
2019, which will allow providers to capture the number of
residents started on antibiotic treatment for CDI that month
based on clinical decisions.
Time
burden for data collection was increased by 10 minutes to
account for the additional variable being added to this form.
These changes will
increase the overall estimated burden for this form by 5,200
hours.
|
57.140
|
Urinary Tract Infection
(UTI) for LTCF
|
No change
|
Response
options were updated for UTI culture requirements of the UTI
criteria section.
|
Responses
to the UTI culture requirements under the UTI criteria section
was changed from “any number” to “no more than
2 species” to better align with urine culture requirements
between NHSN Components.
This change do not
affect the estimated burden of this form.
|
57.141
|
Monthly Reporting Plan for
LTCF
|
No change
|
No change
|
N/A
|
57.142
|
Denominators for LTCF
Locations
|
No change
|
Add
“CDI Treatment Starts” variable.
Increase time
burden for data collection by 10 minutes
|
Adding
the “CDI Treatment Starts” variable will help
facilities determine whether low CDI event rates might be due to
empiric CDI treatment practices. A new process measure will be
incorporated into the monthly summary data on CDI for LTCFs in
2019, which will allow providers to capture the number of
residents started on antibiotic treatment for CDI that month
based on clinical decisions.
Time
burden for data collection was increased by 10 minutes to
account for the additional variable being added to this form.
These changes will
increase the overall estimated burden for this form by 5,200
hours.
|
57.143
|
Prevention Process
Measures Monthly Monitoring for LTCF
|
No change
|
No change
|
N/A
|
57.150
|
Patient Safety Component-
Annual Facility Survey for LTAC
|
No change
|
Increase
in time burden by 10 minutes.
Question
modified for questions #1, #6,#7, #9, #19
Response
options modified for questions #2, #5, #6, #9, #14-#17
New
required question added for #5, #8, #10,#20, #23-32
Questions
#11,#22, #23-#32 from previous survey removed or replaced
New
optional questions added for #33-42
|
Time
burden increased to account for form changes included in ICR.
Time burden for both data collection tools from 60 to 70
minutes.
Modified
question language for question #1 to include “bacterial”
for the type of antimicrobial susceptibility testing. Adding the
word was done to clarify the existing question and differentiate
it from the same question about fungal testing later (#7).
Wording clarification for question #6 added. For #9 the question
was enhanced to include testing that occurs at both facilities
and outside laboratory testing. The emergence of Candida auris
in the U.S it’s more important to get a sense of how many
facilities have access to labs (whether it's their own or
outside the lab) that use methods that can accurately identify
C. auris. Question #19 contains clarification to include
patients admitted to non-NICU settings in order to differentiate
from a new question (#20) added.
New
answer options included on #2 to reflect current advanced
testing instruments (ATI) being used bacterial antimicrobial
susceptibility testing.Also a wording correction for one of the
test method names that was previously “Other micro broth
dilution method”; it’s been corrected to “Other
broth microdilution method”. New response options added to
#5 to include updated ATI for carbapenemase testing. Answer
options for antimicrobial susceptibility testing (AST) methods
on question #6, “Vitek (legacy)”Microscan Walkaway
rapid” have become obsolete and have been removed. Methods
“MicroScan WalkAway”, “MicroScan autoSCAN”,
“Birby-Bauer disk diffusion”, and Accelerate Pheno”
were all added as options to address an update in new AST
methods technology. Response option for #9 “Broth
macrodilution” was removed due to it becoming obsolete.
Response options for questions #14-17 have been changed in order
to remove the mutually exclusive categorization. Respondents
will now select “Yes” “No” or “Not
applicable” to the question. If “Yes” is
selected, respondents will then select one option to indicate
the contact precautions taken.
Secondary
question added to #5 to gather information about a policy in
place to notify hospital personnel when carbapenemase is
detected to inform prevention and protocol practices implemented
by DHQP. Question #8 added because 50% of C. auris isolates in
the U.S. are from non-blood sites and there is currently no
question on the survey to enumerate this appropriately. Question
#10 added to capture further details about the scenario’s
that exist for antifungal susceptibility testing (AFST) to be
conducted. AFST is typically not included in routine Candida
testing that other survey questions inquire about. Question #20
added to specifically identify routine screening for MRSA of
neonatal units. Neonatal indication screening of MRSA differs
greatly from adults and pediatrics, and in turn, predictors of
antimicrobial use would be different. Questions #23-32 are
replacing previous questions related to Antibiotic Stewardship
Practices (ASP) on the previous survey. Analysis conducted found
that the previous ASP survey questions did not provide enough
description of facilities current Antibiotic Stewardship
Programs based on the CDC developed Core Elements of Hospital
Antibiotic Stewardship guidelines. These guidelines are part of
the larger CDC action plan of Combating Antibiotic-resistant
Bacteria. The new questions will add granularity to provide a
better depiction of hospitals current stewardship programs.
From
the previous survey, Question #11 was removed because CDC no
longer recommends production of antibiograms which removes the
utility of the responses. Question #22 was removed because it
did not produce useful information to our prevention and
response branch upon analysis. Question #23-33 were replaced by
questions #23-32 on the new form to align better with the Core
Elements of Hospital Antibiotic Stewardship guidelines from CDC
to better describe current stewardship programs.
New
optional questions about hospitals antibiotic stewardship
practices were added to add supplemental detail from required
questions #33-42 of the same topic.
These
changes will increase the overall annual estimated burden of form
57.150 by 183 hours and form 57.151 by 400 hours.
|
57.151
|
Patient Safety
Component-Annual Facility Survey for IRF
|
No change
|
57.200
|
Healthcare Personnel
Safety Component Annual Facility Survey
|
No change
|
No change
|
N/A
|
57.203
|
Healthcare Personnel
Safety Monthly Reporting Plan
|
No change
|
Increase the
number of reporting facilities from 17,00 to 0.
|
The
number of reporting facilities has been decreased to account for
the new flu vaccination waiver for facilities required to report
to a CMS program such as IQR, IPF, IRF, LTAC, ASC, and Dialysis.
This change will
increase the overall annual estimated burden of this form by
1,417 hours.
|
57.204
|
Healthcare Worker
Demographic Data
|
No change
|
No change
|
N/A
|
57.205
|
Exposure to Blood/Body
Fluids
|
No change
|
No change
|
N/A
|
57.206
|
Healthcare Worker
Prophylaxis/Treatment
|
No change
|
No change
|
N/A
|
57.207
|
Follow-Up Laboratory
Testing
|
No change
|
No change
|
N/A
|
57.210
|
Healthcare Worker
Prophylaxis/Treatment-Influenza
|
No change
|
No change
|
N/A
|
57.300
|
Hemovigilance Module
Annual Survey
|
No change
|
Updates
were made to the Facility characteristics section of the form to
auto-populate facility information in the NHSN Application.
Question
#17 removed from the survey.
Time burden
reduction by a total of 45 minutes, from 2 hours to 1 hour and
25 minutes to complete.
|
NHSN
will be incorporating instructions about auto-populated data in
the application to reflect data entered into the form, which
will provide additional clarity to users completing the form and
increase the quality of data entered into NHSN.
Question
#17 requested an annual sum of all transfused components and
based on further analysis the form was not completed by many
facilities, therefore, is being deleted from the survey.
These
changes will decrease the overall annual estimated burden of the
form by 292 hours.
|
57.301
|
Hemovigilance Module
Monthly Reporting Plan
|
No change
|
No change
|
N/A
|
57.303
|
Hemovigilance Module
Monthly Reporting Denominators
|
No change
|
No change
|
N/A
|
57.304
|
Hemovigilance Adverse
Reaction
|
No change
|
No change
|
N/A
|
57.305
|
Hemovigilance Incident
|
No change
|
No change
|
N/A
|
57.306
|
Hemovigilance Module
Annual Survey - Non-Acute Care Facility
|
No change
|
No change
|
N/A
|
57.307
|
Hemovigilance Adverse
Reaction - Acute Hemolytic Transfusion Reaction
|
No change
|
Response
options were updated to remove the “H1 receptor blockers"
from the Patient Treatment sections of forms 57.307-57.320.
Updated
response options in the Investigation results in sections of
forms to indicate “No treatment” for forms
57.307-57.320.
Added
seven additional response options for “patient blood type”
in the Patient Information sections of forms57.307-57.320.
|
Based
on user feedback CDC has decided to update response options to
provide clarity in the response options that can be entered into
NHSN. This will reduce the burden of hours it takes facilities
to report non-acute adverse reactions for forms 57.307- 57.320.
Added
‘No treatment’ as a response option under the
Investigation Results in sections of forms 57.307- 57.320 to
allow users the option to indicate the treatment provided, which
will improve data quality.
Modified
response options for “patient blood type” in the
Patient Information sections of forms 57.307-57.320 to further
identify patient blood types, which will improve data quality.
These changes do not
affect the estimated burden of this form.
|
57.308
|
Hemovigilance Adverse
Reaction - Allergic Transfusion Reaction
|
No change
|
These changes do not
affect the estimated burden of this form.
|
57.309
|
Hemovigilance Adverse
Reaction - Delayed Hemolytic Transfusion Reaction
|
No change
|
These changes do not
affect the estimated burden of this form.
|
57.310
|
Hemovigilance Adverse
Reaction - Delayed Serologic Transfusion Reaction
|
No change
|
These changes do not
affect the estimated burden of this form.
|
57.311
|
Hemovigilance Adverse
Reaction - Febrile Non-hemolytic Transfusion Reaction
|
No change
|
These changes do not
affect the estimated burden of this form.
|
57.312
|
Hemovigilance Adverse
Reaction - Hypotensive Transfusion Reaction
|
No change
|
These changes do not
affect the estimated burden of this form.
|
57.313
|
Hemovigilance Adverse
Reaction - Infection
|
No change
|
These changes do not
affect the estimated burden of this form.
|
57.314
|
Hemovigilance Adverse
Reaction - Post Transfusion Purpura
|
No change
|
These changes do not
affect the estimated burden of this form.
|
57.315
|
Hemovigilance Adverse
Reaction - Transfusion Associated Dyspnea
|
No change
|
These changes do not
affect the estimated burden of this form.
|
57.316
|
Hemovigilance Adverse
Reaction - Transfusion Associated Graft vs. Host Disease
|
No change
|
These changes do not
affect the estimated burden of this form.
|
57.317
|
Hemovigilance Adverse
Reaction - Transfusion Related Acute Lung Injury
|
No change
|
These changes do not
affect the estimated burden of this form.
|
57.318
|
Hemovigilance Adverse
Reaction - Transfusion Associated Circulatory Overload
|
No change
|
These changes do not
affect the estimated burden of this form.
|
57.319
|
Hemovigilance Adverse
Reaction - Unknown Transfusion Reaction
|
No change
|
These changes do not
affect the estimated burden of this form.
|
57.320
|
Hemovigilance Adverse
Reaction - Other Transfusion Reaction
|
No change
|
These changes do not
affect the estimated burden of this form.
|
57.400
|
Outpatient Procedure
Component—Annual Facility Survey
|
No change
|
No change
|
N/A
|
57.401
|
Outpatient Procedure
Component - Monthly Reporting Plan
|
No change
|
No change
|
N/A
|
57.402
|
Outpatient Procedure
Component Same Day Outcome Measures
|
No change
|
No change
|
N/A
|
57.403
|
Outpatient Procedure
Component - Monthly Denominators for Same Day Outcome Measures
|
No change
|
No change
|
N/A
|
57.404
|
Outpatient Procedure
Component – SSI Denominators
|
No change
|
No change
|
N/A
|
57.405
|
Outpatient Procedure
Component - Surgical Site (SSI) Event
|
No change
|
No change
|
N/A
|
57.500
|
Outpatient Dialysis Center
Practices Survey
|
No change
|
Added
question to Section A.1 #3.
Modify
section header for section E2.
Modify
response options for #53, #54bii, #55, and #57.
The time burden to
complete this for was increased by two minutes.
|
Question
added to have an accurate count of facilities who are accredited
by an organization outside of CMS.
Modified
section header from “Dialysate” to“Water/Dialysate”
to better reflect the information captured in this section.
Revisions
are being made to the question, “Before cannulation, what
is the buttonhole site most often prepped with?” for all
questions listed. Responses for questions #53, #54bii, and #55
will be revised from“chlorhexidine with alcohol (e.g.,
Chloraprep®, Chlorasrub™)” and updated to
“chlorhexidine with alcohol (e.g., Chloarprep™, PDI
Prevantics®)” to capture products that meet or exceed
the chlorhexidine recommendation. For #57, response option is
being revised from “chlorhexidine with alcohol (e.g.,
Chloraprep®, Chlorasrub™)” to “chlorhexidine”.
Time
burden to complete the form was increased from 125 minutes to
127 minutes.
These changes result in
an increase of 13,883 burden hours for this form.
|
57.501
|
Dialysis Monthly Reporting
Plan
|
No change
|
Modify
responses for Prevention Process Measures.
|
The
‘Injection Safety’ field of the Prevention Process
Measures (PPM) summary form was split into two fields:
‘Injection Safety- Medication Preparation’ and
‘Injection Safety – Medication Administration’.
We are modifying the ‘Injection Safety’ field on the
MRP to align with the PPM summary form to allow a user to
indicate which injection safety practice(s) they are observing
in-plan.
These changes will not
have an impact on the overall annual burden for this form.
|
57.502
|
Dialysis Event
|
No change
|
No change
|
No change
|
57.503
|
Denominators for Dialysis
Event Surveillance
|
No change
|
No change
|
N/A
|
57.504
|
Prevention Process
Measures Monthly Monitoring for Dialysis
|
No change
|
The
number of respondents decreased from 2,000 to 1,000.
|
The
number of respondents was decreased from 2,000 to 1,000 because
the number of facilities reporting has not adopted the use of
the form.
This change will result
in a decrease of 13,000 burden hours for this form.
|
57.505
|
Dialysis Patient Influenza
Vaccination
|
No change
|
No change
|
N/A
|
57.506
|
Dialysis Patient Influenza
Vaccination Denominator
|
No change
|
No change
|
N/A
|
57.507
|
Home Dialysis Center
Practices Survey
|
No change
|
No change
|
N/A
|